28322271|t|Mechanistic and structural basis of bioengineered bovine Cathelicidin-5 with optimized therapeutic activity
28322271|a|Peptide - drug discovery using host-defense peptides becomes promising against antibiotic - resistant pathogens and cancer cells. Here, we customized the therapeutic activity of bovine cathelicidin-5 targeting to bacteria, protozoa, and tumor cells. The membrane dependent conformational adaptability and plasticity of cathelicidin-5 is revealed by biophysical analysis and atomistic simulations over 200 Î¼s in thymocytes, leukemia, and E. coli cell-membranes. Our understanding of energy - dependent cathelicidin-5 intrusion in heterogeneous membranes aided in designing novel loss/gain-of-function analogues. In vitro findings identified leucine-zipper to phenylalanine substitution in cathelicidin-5 (1-18) significantly enhance the antimicrobial and anticancer activity with trivial hemolytic activity. Targeted mutants of cathelicidin-5 at kink region and N-terminal truncation revealed loss-of-function. We ensured the existence of a bimodal mechanism of peptide action (membranolytic and non-membranolytic) in vitro. The melanoma mouse model in vivo study further supports the in vitro findings. This is the first structural report on cathelicidin-5 and our findings revealed potent therapeutic application of designed cathelicidin-5 analogues.
28322271	0	11	Mechanistic	T169	C0443254
28322271	16	26	structural	T082	C0678594
28322271	27	32	basis	T169	C1527178
28322271	36	49	bioengineered	T091	C0005539
28322271	50	56	bovine	T015	C3667982
28322271	57	71	Cathelicidin-5	T116,T123	C0671062
28322271	87	107	therapeutic activity	T061	C0556489
28322271	108	115	Peptide	T116	C0030956
28322271	118	132	drug discovery	T062	C0920472
28322271	139	151	host-defense	T042	C0520990
28322271	152	160	peptides	T116	C0030956
28322271	187	197	antibiotic	T195	C0003232
28322271	200	209	resistant	T169	C0332325
28322271	210	219	pathogens	T001	C0450254
28322271	224	236	cancer cells	T025	C0334227
28322271	262	282	therapeutic activity	T061	C0556489
28322271	286	292	bovine	T015	C3667982
28322271	293	307	cathelicidin-5	T116,T123	C0671062
28322271	321	329	bacteria	T007	C0004611
28322271	331	339	protozoa	T204	C0033739
28322271	345	356	tumor cells	T025	C0597032
28322271	362	370	membrane	T026	C0596901
28322271	371	380	dependent	T080	C0851827
28322271	381	395	conformational	T082	C0026377
28322271	396	408	adaptability	T169	C0456081
28322271	413	423	plasticity	T070	C0678558
28322271	427	441	cathelicidin-5	T116,T123	C0671062
28322271	457	468	biophysical	T091	C0005553
28322271	469	477	analysis	T062	C0936012
28322271	482	503	atomistic simulations	T062	C0679083
28322271	519	529	thymocytes	T025	C0814999
28322271	531	539	leukemia	T191	C0023418
28322271	545	552	E. coli	T007	C0014834
28322271	553	567	cell-membranes	T026	C0007603
28322271	590	596	energy	T070	C0542479
28322271	599	608	dependent	T080	C0851827
28322271	609	623	cathelicidin-5	T116,T123	C0671062
28322271	624	633	intrusion	T061	C0087111
28322271	637	650	heterogeneous	T080	C0019409
28322271	651	660	membranes	T026	C0007603
28322271	680	685	novel	T080	C0205314
28322271	686	707	loss/gain-of-function	T033	C0243095
28322271	708	717	analogues	T104	C0002776
28322271	719	727	In vitro	T080	C1533691
28322271	728	736	findings	T169	C2607943
28322271	748	762	leucine-zipper	T116	C0079686
28322271	766	779	phenylalanine	T116,T121,T123	C0031453
28322271	780	792	substitution	T044	C0596324
28322271	796	810	cathelicidin-5	T116,T123	C0671062
28322271	832	839	enhance	T052	C2349975
28322271	844	857	antimicrobial	T044	C1321418
28322271	862	881	anticancer activity	T033	C0243095
28322271	895	913	hemolytic activity	T034	C2945560
28322271	915	931	Targeted mutants	T049	C0596988
28322271	935	949	cathelicidin-5	T116,T123	C0671062
28322271	953	964	kink region	T082	C1254362
28322271	969	990	N-terminal truncation	T044	C1514568
28322271	1000	1016	loss-of-function	T033	C0243095
28322271	1048	1065	bimodal mechanism	T169	C0441712
28322271	1069	1076	peptide	T116	C0030956
28322271	1077	1083	action	T052	C3266814
28322271	1085	1098	membranolytic	T033	C2825141
28322271	1103	1120	non-membranolytic	T033	C2825141
28322271	1122	1130	in vitro	T080	C1533691
28322271	1136	1144	melanoma	T191	C0025202
28322271	1145	1156	mouse model	T050	C2986594
28322271	1157	1170	in vivo study	T062	C0681829
28322271	1192	1200	in vitro	T080	C1533691
28322271	1201	1209	findings	T169	C2607943
28322271	1250	1264	cathelicidin-5	T116,T123	C0671062
28322271	1273	1281	findings	T169	C2607943
28322271	1298	1321	therapeutic application	T061	C0278296
28322271	1334	1348	cathelicidin-5	T116,T123	C0671062
28322271	1349	1358	analogues	T104	C0002776